Heranova Lifesciences, a Burlington, MA-based biotech company for women’s health, raised $13.5M in Seed+ funding.
Backers included Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital.
The company intends to use the funds to launch a serial of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis.
Led by CEO Dr. Jonathan Y. Zhao, Chief Diagnostic Medical Officer Dr. Farideh Bischoff, Heranova Lifesciences is a biotech company solely focused on developing integrated care solutions for Women’s Health. Their goal is to address needs in women’s healthcare by offering internally developed and externally partnered diagnostics, drugs, and devices. The company has already established presences in the United States and Asia.
FinSMEs
02/01/2024